Search

Your search keyword '"Cholestasis chemically induced"' showing total 1,749 results

Search Constraints

Start Over You searched for: Descriptor "Cholestasis chemically induced" Remove constraint Descriptor: "Cholestasis chemically induced"
1,749 results on '"Cholestasis chemically induced"'

Search Results

1. Vanishing bile duct syndrome: a sequela of temozolomide and levetiracetam-induced cholestatic liver injury.

2. A Comparative Analysis of ADRs under Obeticholic Acid and Ursodeoxycholic Acid in Cholestatic Liver Diseases Using the FAERS Database.

3. Paeoniflorin inhibited GSDMD to alleviate ANIT-induced cholestasis via pyroptosis signaling pathway.

4. Taurocholic acid represents an earlier and more sensitive biomarker and promotes cholestatic hepatotoxicity in ANIT-treated rats.

5. Gly-β-MCA is a potent anti-cholestasis agent against "human-like" hydrophobic bile acid-induced biliary injury in mice.

6. Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC).

7. A metabolomics study on the mechanisms of Gardeniae fructus against α-naphthylisothiocyanate-induced cholestatic liver injury.

8. Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury.

9. Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatment.

10. From hazard to risk prioritization: a case study to predict drug-induced cholestasis using physiologically based kinetic modeling.

11. Tauroursodeoxycholate prevents estradiol 17β-d-glucuronide-induced cholestasis and endocytosis of canalicular transporters by switching off pro-cholestatic signaling pathways.

12. Pirfenidone ameliorates ANIT-induced cholestatic liver injury via modulation of FXR, NF-кB/TNF-α, and Wnt/GSK-3β/β-catenin signaling pathways.

13. Swertia cincta and its main active ingredients regulate the PPAR-α pathway in anti-cholestatic liver injury.

14. Caffeoylquinic acids from Silphium perfoliatum L. show hepatoprotective effects on cholestatic mice by regulating enterohepatic circulation of bile acids.

15. Metabolomics and serum pharmacochemistry combined with network pharmacology uncover the potential effective ingredients and mechanisms of Yin-Chen-Si-Ni Decoction treating ANIT-induced cholestatic liver injury.

16. L-Glutamine mitigates bile acid-induced inhibition of growth factor activity in rat hepatocyte cultures.

17. NADPH oxidase-generated reactive oxygen species are involved in estradiol 17ß-d-glucuronide-induced cholestasis.

18. Formation of functional, extended bile canaliculi, and increased bile acid production in sandwich-cultured human cryopreserved hepatocytes using commercially available culture medium.

19. Mechanistic studies on the alleviation of ANIT-induced cholestatic liver injury by Polygala fallax Hemsl. polysaccharides.

20. Artemisia capillaris Thunb. Polysaccharide alleviates cholestatic liver injury through gut microbiota modulation and Nrf2 signaling pathway activation in mice.

22. The Effects of Aflatoxin B 1 on Liver Cholestasis and Its Nutritional Regulation in Ducks.

23. Gancao decoction attenuates hepatic necroptosis via activating caspase 8 in cholestatic liver injury.

24. Psoralen and Isopsoralen, Two Estrogen -Like Natural Products from Psoraleae Fructus , Induced Cholestasis via Activation of ERK1/2.

25. Cyclosporine A-induced systemic metabolic perturbations in rats: A comprehensive metabolome analysis.

26. Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support.

27. Integrating Mechanistic and Toxicokinetic Information in Predictive Models of Cholestasis.

28. Ursodeoxycholic acid and 18β-glycyrrhetinic acid alleviate ethinylestradiol-induced cholestasis via downregulating RORγt and CXCR3 signaling pathway in iNKT cells.

29. Allocholic acid protects against α-naphthylisothiocyanate-induced cholestasis in mice by ameliorating disordered bile acid homeostasis.

30. Exploring the effect and mechanism of cucurbitacin B on cholestatic liver injury based on network pharmacology and experimental verification.

31. Tacrolimus-induced cholestatic hepatotoxicity after renal transplantation: a case report.

33. Gardenia extract protects against intrahepatic cholestasis by regulating bile acid enterohepatic circulation.

34. Identifying hepatoprotective mechanism and effective components of Yinchenzhufu decoction in chronic cholestatic liver injury using a comprehensive strategy based on metabolomics, molecular biology, pharmacokinetics, and cytology.

35. Ginsenoside Rg1 alleviates ANIT-induced cholestatic liver injury by inhibiting hepatic inflammation and oxidative stress via SIRT1 activation.

36. Detrimental Role of CXCR3 in α-Naphthylisothiocyanate- and Triptolide-Induced Cholestatic Liver Injury.

37. Obeticholic acid protects against lithocholic acid-induced exogenous cell apoptosis during cholestatic liver injury.

38. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress.

39. Management of Tacrolimus-Induced Toxicity With Normal Serum Levels After Liver Transplant.

40. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

41. The protective effect of forsythiaside A on 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced cholestatic liver injury in mice: Based on targeted metabolomics and molecular biology technology.

42. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma.

43. Unraveling the mechanisms underlying drug-induced cholestatic liver injury: identifying key genes using machine learning techniques on human in vitro data sets.

44. Yinchen decoction protects against cholic acid diet-induced cholestatic liver injury in mice through liver and ileal FXR signaling.

45. Multi-omics reveals 2-bromo-4,6-dinitroaniline (BDNA)-induced hepatotoxicity and the role of the gut-liver axis in rats.

46. Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach.

47. AMP-activated protein kinase-farnesoid X receptor pathway contributes to oleanolic acid-induced liver injury.

48. Molecular mechanisms of hepatoprotective effect of tectorigenin against ANIT-induced cholestatic liver injury: Role of FXR and Nrf2 pathways.

49. Gentamicin alleviates cholestatic liver injury by decreasing gut microbiota-associated bile salt hydrolase activity in rats.

50. Factors associated with cholestasis in newborns with gastroschisis.

Catalog

Books, media, physical & digital resources